The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Radiotherapy

  • Cisplatin, given daily in combination with the radiotherapy described here to patients with nonmetastatic but inoperable non-small-cell lung cancer, improved rates of survival and control of local disease at the price of substantial side effects [1].
  • Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy [2].
  • Prior thoracic radiotherapy appeared to predispose to bleomycin pulmonary toxicity, as this complication developed in five of 12 patients receiving prior chest radiotherapy vs four of 89 not receiving radiotherapy (p less than .001) [3].
  • BACKGROUND: Chemotherapy, with or without radiotherapy, results in a 30%-40% complete response rate in small-cell lung cancer (SCLC), but approximately 90% of patients who have complete remission die within 2 years after relapse with chemoresistant disease [4].
  • Local control of a mammary carcinoma in air-breathing C3H mice was enhanced by giving metronidazole before radiotherapy; When 0.5-1.0 mg metronidazole/g body weight was given ip 10 minutes before irradiation, the dose required for local control of 50% of the tumors (TCD50) was reduced by a factor of 1.37-1.38 [5].

Psychiatry related information on Radiotherapy


High impact information on Radiotherapy


Chemical compound and disease context of Radiotherapy


Biological context of Radiotherapy


Anatomical context of Radiotherapy


Associations of Radiotherapy with chemical compounds


Gene context of Radiotherapy

  • These results also encourage further development of EGFR targeting combined with fractionated radiotherapy in HNSCC [35].
  • Of those patients subsequently treated with radiation, VEGF levels at presentation between patients with no evidence of disease (NED) after radiation and those who had persistent or recurrent disease after radiotherapy were also different (P =.039) [36].
  • Thus, COX-2 inhibitors have a high potential for increasing the therapeutic ratio of radiotherapy [37].
  • However, in a recent randomized, placebo-controlled trial involving patients receiving curative radiotherapy for squamous cell carcinoma of the head and neck, erythropoietin treatment was associated with poorer locoregional progression-free survival [38].
  • CONCLUSIONS: Expression levels of both APE1 and XRCC1 proteins were strongly associated with patient outcome following radiotherapy, separating patients with good outcome from the 50% with poor outcome (82% and 44%, 3-year cause-specific survival, respectively) [39].

Analytical, diagnostic and therapeutic context of Radiotherapy


  1. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A. N. Engl. J. Med. (1992) [Pubmed]
  2. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., Holmberg, L. Nat. Med. (1995) [Pubmed]
  3. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. Samuels, M.L., Johnson, D.E., Holoye, P.Y., Lanzotti, V.J. JAMA (1976) [Pubmed]
  4. Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. Pujol, J.L., Gibney, D.J., Su, J.Q., Maksymiuk, A.W., Jett, J.R. J. Natl. Cancer Inst. (1993) [Pubmed]
  5. Metronidazole: effect on radiosensitivity of tumor and normal tissues in mice. Stone, H.B., Withers, H.R. J. Natl. Cancer Inst. (1975) [Pubmed]
  6. The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. Ohebshalom, M., Parker, M., Guhring, P., Mulhall, J.P. J. Urol. (2005) [Pubmed]
  7. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity. Serkies, K., Jassem, J. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  8. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Yao, M., Smith, R.B., Graham, M.M., Hoffman, H.T., Tan, H., Funk, G.F., Graham, S.M., Chang, K., Dornfeld, K.J., Menda, Y., Buatti, J.M. Int. J. Radiat. Oncol. Biol. Phys. (2005) [Pubmed]
  9. Oxorhenium(V) and oxotechnetium(V) [NN][S]3 complexes of 2-phenylbenzothiazole derivatives. Tzanopoulou, S., Pirmettis, I.C., Patsis, G., Raptopoulou, C., Terzis, A., Papadopoulos, M., Pelecanou, M. Inorganic chemistry. (2006) [Pubmed]
  10. Sequential high-dose treatment with peripheral blood progenitor cell transplantation in patients with multiple myeloma. Goldschmidt, H., Hegenbart, U., Moos, M., Eugenhart, R., Wannenmacher, M., Haas, R., Hunstein, W. Stem Cells (1995) [Pubmed]
  11. Use of antioxidants during chemotherapy and radiotherapy should be avoided. D'Andrea, G.M. CA: a cancer journal for clinicians. (2005) [Pubmed]
  12. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. Macdonald, J.S., Smalley, S.R., Benedetti, J., Hundahl, S.A., Estes, N.C., Stemmermann, G.N., Haller, D.G., Ajani, J.A., Gunderson, L.L., Jessup, J.M., Martenson, J.A. N. Engl. J. Med. (2001) [Pubmed]
  13. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. Keller, S.M., Adak, S., Wagner, H., Herskovic, A., Komaki, R., Brooks, B.J., Perry, M.C., Livingston, R.B., Johnson, D.H. N. Engl. J. Med. (2000) [Pubmed]
  14. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. Brizel, D.M., Albers, M.E., Fisher, S.R., Scher, R.L., Richtsmeier, W.J., Hars, V., George, S.L., Huang, A.T., Prosnitz, L.R. N. Engl. J. Med. (1998) [Pubmed]
  15. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. Curtis, R.E., Boice, J.D., Stovall, M., Bernstein, L., Greenberg, R.S., Flannery, J.T., Schwartz, A.G., Weyer, P., Moloney, W.C., Hoover, R.N. N. Engl. J. Med. (1992) [Pubmed]
  16. Control of local tumor growth with combined fractionated radiotherapeutic and chemotherapeutic regimens. Poulakos, L., Schenken, L.L., Hagemann, R.F., Burholt, D.R., Lesher, S. J. Natl. Cancer Inst. (1975) [Pubmed]
  17. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. Travis, L.B., Curtis, R.E., Glimelius, B., Holowaty, E.J., Van Leeuwen, F.E., Lynch, C.F., Hagenbeek, A., Stovall, M., Banks, P.M., Adami, J. J. Natl. Cancer Inst. (1995) [Pubmed]
  18. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. Andersson, M., Storm, H.H., Mouridsen, H.T. J. Natl. Cancer Inst. (1991) [Pubmed]
  19. Preferential cytotoxicity of 5-thio-D-glucose against hypoxic tumor cells. Song, C.W., Clement, J.J., Levitt, S.H. J. Natl. Cancer Inst. (1976) [Pubmed]
  20. Effects of combined radiotherapy and immunotherapy with the use of pyran copolymer on murine fibrosarcoma. Collins, A.L., Song, C.W. J. Natl. Cancer Inst. (1978) [Pubmed]
  21. Induction of p53 expression in skin by radiotherapy and UV radiation: a randomized study. Ponten, F., Lindman, H., Bostrom, A., Berne, B., Bergh, J. J. Natl. Cancer Inst. (2001) [Pubmed]
  22. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. Herr, I., Wilhelm, D., Böhler, T., Angel, P., Debatin, K.M. EMBO J. (1997) [Pubmed]
  23. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Khodarev, N.N., Beckett, M., Labay, E., Darga, T., Roizman, B., Weichselbaum, R.R. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  24. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. Raybaud-Diogène, H., Fortin, A., Morency, R., Roy, J., Monteil, R.A., Têtu, B. J. Clin. Oncol. (1997) [Pubmed]
  25. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. Pollack, A., Grignon, D.J., Heydon, K.H., Hammond, E.H., Lawton, C.A., Mesic, J.B., Fu, K.K., Porter, A.T., Abrams, R.A., Shipley, W.U. J. Clin. Oncol. (2003) [Pubmed]
  26. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. Hortobagyi, G.N., Buzdar, A.U., Theriault, R.L., Valero, V., Frye, D., Booser, D.J., Holmes, F.A., Giralt, S., Khouri, I., Andersson, B., Gajewski, J.L., Rondon, G., Smith, T.L., Singletary, S.E., Ames, F.C., Sneige, N., Strom, E.A., McNeese, M.D., Deisseroth, A.B., Champlin, R.E. J. Natl. Cancer Inst. (2000) [Pubmed]
  27. Combined-modality oncotherapy with cyclophosphamide (NSC-26271) and radiotherapy: control of murine mastocytoma. Schenken, L.L., Hagemann, R.F., Burholt, D.R., Lesher, S. J. Natl. Cancer Inst. (1976) [Pubmed]
  28. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Greco, F.A., Brereton, H.D., Kent, H., Zimbler, H., Merrill, J., Johnson, R.E. Ann. Intern. Med. (1976) [Pubmed]
  29. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. Pearcey, R., Brundage, M., Drouin, P., Jeffrey, J., Johnston, D., Lukka, H., MacLean, G., Souhami, L., Stuart, G., Tu, D. J. Clin. Oncol. (2002) [Pubmed]
  30. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. Poortmans, P.M., Kluin-Nelemans, H.C., Haaxma-Reiche, H., Van't Veer, M., Hansen, M., Soubeyran, P., Taphoorn, M., Thomas, J., Van den Bent, M., Fickers, M., Van Imhoff, G., Rozewicz, C., Teodorovic, I., van Glabbeke, M. J. Clin. Oncol. (2003) [Pubmed]
  31. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. Keys, H.M., Bundy, B.N., Stehman, F.B., Muderspach, L.I., Chafe, W.E., Suggs, C.L., Walker, J.L., Gersell, D. N. Engl. J. Med. (1999) [Pubmed]
  32. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. Walker, M.D., Green, S.B., Byar, D.P., Alexander, E., Batzdorf, U., Brooks, W.H., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Mealey, J., Owens, G., Ransohoff, J., Robertson, J.T., Shapiro, W.R., Smith, K.R., Wilson, C.B., Strike, T.A. N. Engl. J. Med. (1980) [Pubmed]
  33. Leukemia following Hodgkin's disease. Kaldor, J.M., Day, N.E., Clarke, E.A., Van Leeuwen, F.E., Henry-Amar, M., Fiorentino, M.V., Bell, J., Pedersen, D., Band, P., Assouline, D. N. Engl. J. Med. (1990) [Pubmed]
  34. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. Hong, W.K., Lippman, S.M., Itri, L.M., Karp, D.D., Lee, J.S., Byers, R.M., Schantz, S.P., Kramer, A.M., Lotan, R., Peters, L.J. N. Engl. J. Med. (1990) [Pubmed]
  35. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. Bentzen, S.M., Atasoy, B.M., Daley, F.M., Dische, S., Richman, P.I., Saunders, M.I., Trott, K.R., Wilson, G.D. J. Clin. Oncol. (2005) [Pubmed]
  36. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. Chan, L.W., Moses, M.A., Goley, E., Sproull, M., Muanza, T., Coleman, C.N., Figg, W.D., Albert, P.S., Ménard, C., Camphausen, K. J. Clin. Oncol. (2004) [Pubmed]
  37. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Kishi, K., Petersen, S., Petersen, C., Hunter, N., Mason, K., Masferrer, J.L., Tofilon, P.J., Milas, L. Cancer Res. (2000) [Pubmed]
  38. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Arcasoy, M.O., Amin, K., Chou, S.C., Haroon, Z.A., Varia, M., Raleigh, J.A. Clin. Cancer Res. (2005) [Pubmed]
  39. APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Sak, S.C., Harnden, P., Johnston, C.F., Paul, A.B., Kiltie, A.E. Clin. Cancer Res. (2005) [Pubmed]
  40. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. Rutqvist, L.E., Mattsson, A. J. Natl. Cancer Inst. (1993) [Pubmed]
  41. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. Lefebvre, J.L., Chevalier, D., Luboinski, B., Kirkpatrick, A., Collette, L., Sahmoud, T. J. Natl. Cancer Inst. (1996) [Pubmed]
  42. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Overgaard, M., Jensen, M.B., Overgaard, J., Hansen, P.S., Rose, C., Andersson, M., Kamby, C., Kjaer, M., Gadeberg, C.C., Rasmussen, B.B., Blichert-Toft, M., Mouridsen, H.T. Lancet (1999) [Pubmed]
  43. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study. Sullivan, M.P., Chen, T., Dyment, P.G., Hvizdala, E., Steuber, C.P. Blood (1982) [Pubmed]
WikiGenes - Universities